Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 18, 2022 - Issue 6
Submit an article Journal homepage
1,734
Views
1
CrossRef citations to date
0
Altmetric
HPV – Research Paper

Safety and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial

Zhao-Jun Moa Expanded Program on Immunization Department, Guangxi Center for Disease Control and Prevention, Nanning, Guangxi, ChinaView further author information
,
Zhao-Feng Bib State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, ChinaView further author information
,
Wei Shengb State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, ChinaView further author information
,
Qi Chenb State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, ChinaView further author information
,
Teng Huanga Expanded Program on Immunization Department, Guangxi Center for Disease Control and Prevention, Nanning, Guangxi, ChinaView further author information
,
Ming-Qiang Lic Liuzhou Center for Disease Control and Prevention, Liuzhou, Guangxi, ChinaView further author information
,
Xue-Lian Cuic Liuzhou Center for Disease Control and Prevention, Liuzhou, Guangxi, ChinaView further author information
,
Ya-Hui Wangjiangb State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, ChinaView further author information
,
Bi-Zhen Lind Vaccine R&D Department, Xiamen Innovax Biotech Company, Xiamen, Fujian, ChinaView further author information
,
Feng-Zhu Zhengd Vaccine R&D Department, Xiamen Innovax Biotech Company, Xiamen, Fujian, ChinaView further author information
,
Guang Sund Vaccine R&D Department, Xiamen Innovax Biotech Company, Xiamen, Fujian, ChinaView further author information
,
Ya-Fei Lib State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, ChinaView further author information
,
Ya Zhengb State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, ChinaView further author information
,
Si-Jie Zhuangb State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, ChinaView further author information
,
Ying-Ying Sub State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, ChinaView further author information
,
Hui-Rong Pand Vaccine R&D Department, Xiamen Innovax Biotech Company, Xiamen, Fujian, ChinaCorrespondence[email protected]
View further author information
,
Shou-Jie Huangb State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, ChinaCorrespondence[email protected]
View further author information
,
Ting Wub State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1806-3056View further author information
ORCID Icon,
Jun Zhangb State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, ChinaORCID Iconhttps://orcid.org/0000-0002-6601-9180View further author information
ORCID Icon &
Ning-Shao Xiab State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, ChinaORCID Iconhttps://orcid.org/0000-0003-0179-5266View further author information
ORCID Icon show all
Article: 2092363 | Received 15 Apr 2022, Accepted 17 Jun 2022, Published online: 14 Jul 2022

References

  • Lacey CJN, Guimera N, Garland SM. Chapter 10 - low-risk human papillomavirus: genital warts, cancer and respiratory papillomatosis. In: Jenkins D, Bosch F, editors. Human papillomavirus. Academic Press; 2020. p. 1–11.
  • Wei F, Sheng W, Wu X, Yin K, Lan J, Huang Y, Ma X, Zheng Y, Zhuang S, Huang S, et al. Incidence of anogenital warts in Liuzhou, South China: a comparison of data from a prospective study and from the national surveillance system. Emerg Microbes Infect. 2017;6(1):e113. doi:10.1038/emi.2017.100.
  • Park IU, Introcaso C, Dunne EF. Human papillomavirus and genital warts: a review of the evidence for the 2015 centers for disease control and prevention sexually transmitted diseases treatment guidelines. Clin Infect Dis. 2015;61(Suppl 8):S849–55. doi:10.1093/cid/civ813.
  • Yue X, Gong X, Li J, Teng F., Jiang N, Men P, Wang J, Wang Y, Chen X, Gu H. Epidemiological features of condyloma acuminatum in national sexually transmitted disease surveillance sites in China from 2008 to 2016. Chinese Journal of Dermatology. 2017;50:321–325.
  • Patel H, Wagner M, Singhal P, Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis. 2013;13(1):39. doi:10.1186/1471-2334-13-39.
  • Moreira ED Jr., Giuliano AR, Palefsky J, Flores CA, Goldstone S, Ferris D, Hillman RJ, Moi H, Stoler MH, Marshall B, et al. Incidence, clearance, and disease progression of genital human papillomavirus infection in heterosexual men. J Infect Dis. 2014;210(2):192–199. doi:10.1093/infdis/jiu077.
  • Dareng EO, Adebamowo SN, Famooto A, Olawande O, Odutola MK, Olaniyan Y, et al. Prevalence and incidence of genital warts and cervical Human Papillomavirus infections in Nigerian women. BMC Infect Dis. 2019;19:27. doi:10.1186/s12879-018-3582-y.
  • Su S, Chow EP, Muessig KE, Yuan L, Tucker JD, Zhang X, Ren J, Fairley CK, Jing J, Zhang L, et al. Sustained high prevalence of viral hepatitis and sexually transmissible infections among female sex workers in China: a systematic review and meta-analysis. BMC Infect Dis. 2016;16(1):2. doi:10.1186/s12879-015-1322-0.
  • Lukacs A, Mate Z, Farkas N, Miko A, Tenk J, Hegyi P, Németh B, Czumbel LM, Wuttapon S, Kiss I, et al. The quadrivalent HPV vaccine is protective against genital warts: a meta-analysis. BMC Public Health. 2020;20(1):691. doi:10.1186/s12889-020-08753-y.
  • Qi SZ, Wang SM, Shi JF, Wang QQ, Chen XS, Sun LJ, Liu A, Zhang N, Jiang N, Siva P, et al. Human papillomavirus-related psychosocial impact of patients with genital warts in China: a hospital-based cross-sectional study. BMC Public Health. 2014;14(1):739. doi:10.1186/1471-2458-14-739.
  • Mortensen GL, Larsen HK. The quality of life of patients with genital warts: a qualitative study. BMC Public Health. 2010;10(1):113. doi:10.1186/1471-2458-10-113.
  • Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, Wand H, Fairley CK. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis. 2011;11(1):39–44. doi:10.1016/S1473-3099(10)70225-5.
  • Drolet M, Benard E, Perez N, Brisson M, Ali H, Boily M-C, Baldo V, Brassard P, Brotherton JML, Callander D; Group HPVVIS. Population-Level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019;394(10197):497–509. doi:10.1016/S0140-6736(19)30298-3.
  • Flagg EW, Torrone EA. Declines in anogenital warts among age groups most likely to be impacted by human papillomavirus vaccination, United States, 2006–2014. Am J Public Health. 2018;108(1):112–119. doi:10.2105/AJPH.2017.304119.
  • Herweijer E, Ploner A, Sparen P. Substantially reduced incidence of genital warts in women and men six years after HPV vaccine availability in Sweden. Vaccine. 2018;36:1917–1920. doi:10.1016/j.vaccine.2018.02.097.
  • Paul P, Fabio A. Literature review of HPV vaccine delivery strategies: considerations for school- and non-school based immunization program. Vaccine. 2014;32:320–326. doi:10.1016/j.vaccine.2013.11.070.
  • Ng SS, Hutubessy R, Chaiyakunapruk N. Systematic review of cost-effectiveness studies of human papillomavirus (HPV) vaccination: 9-valent vaccine, gender-neutral and multiple age cohort vaccination. Vaccine. 2018;36(19):2529–2544. doi:10.1016/j.vaccine.2018.03.024.
  • van der Loeff SMF, Vorsters A, Marra E, Van Damme P, Hogewoning A. Should female sex workers be offered HPV vaccination? Hum Vaccin Immunother. 2019;15:1544–1548. doi:10.1080/21645515.2019.1602432.
  • Lin A, Ong KJ, Hobbelen P, King E, Mesher D, Edmunds WJ, Sonnenberg P, Gilson R, Bains I, Choi YH, et al. Impact and cost-effectiveness of selective human papillomavirus vaccination of men who have sex with men. Clin Infect Dis. 2017;64(5):580–588. doi:10.1093/cid/ciw845.
  • Qiao YL, Wu T, Li RC, Hu YM, Wei LH, Li CG, Chen W, Huang S-J, Zhao F-H, Li M-Q, et al. Efficacy, safety, and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine: an interim analysis of a randomized clinical trial. J Natl Cancer Inst. 2020;112(2):145–153. doi:10.1093/jnci/djz074.
  • Pan H, Li Z, Wang J, Song S, Wang D, Wei M, Gu Y, Zhang J, Li S, Xia N, et al. Bacterially expressed human papillomavirus type 6 and 11 bivalent vaccine: characterization, antigenicity and immunogenicity. Vaccine. 2017;35(24):3222–3231. doi:10.1016/j.vaccine.2017.04.064.
  • Hu YM, Guo M, Li CG, Chu K, He WG, Zhang J, Gu J-X, Li J, Zhao H, Wu X-H, et al. Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women. Sci China Life Sci. 2020;63(4):582–591. doi:10.1007/s11427-019-9547-7.
  • Zhao H, Lin ZJ, Huang SJ, Li J, Liu XH, Guo M, Zhang J, Xia N-S, Pan H-R, Wu T, et al. Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination. Hum Vaccin Immunother. 2014;10(3):740–746. doi:10.4161/hv.27619.
  • Moreira ED Jr., Block SL, Ferris D, Giuliano AR, Iversen OE, Joura EA, Kosalaraksa P, Schilling A, Van Damme P, Bornstein J, et al. Safety profile of the 9-valent HPV vaccine: a combined analysis of 7 phase III clinical trials. Pediatrics. 2016;138(2): 2015–4387. 10.1542/peds.2015-4387.
  • Castellsague X, Munoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, Luna J, Myers E, Mallary S, Bautista OM, et al. End-Of-Study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Br J Cancer. 2011;105(1):28–37. doi:10.1038/bjc.2011.185.
  • Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372:711–723. doi:10.1056/NEJMoa1405044.
  • Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GWK, Ferris DG, Steben M, Bryan J, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928–1943. doi:10.1056/NEJMoa061760.
  • Goldstone SE, Giuliano AR, Palefsky JM, Lazcano-Ponce E, Penny ME, Cabello RE, et al. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2021:10. doi: 10.1016/S1473-3099(21)00327-3.
  • Huang X, Wang X, Zhang J, Xia N, Zhao Q. Escherichia coli-derived virus-like particles in vaccine development. NPJ Vaccines. 2017;2(1):3. doi:10.1038/s41541-017-0006-8.
  • Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, Wang H, Yang C-L, Jiang H-M, Cai J-P, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet. 2010;376(9744):895–902. doi:10.1016/S0140-6736(10)61030-6.
  • Dessy FJ, Giannini SL, Bougelet CA, Kemp TJ, David MP, Poncelet SM, Pinto LA, Wettendorff MA. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin. 2008;4(6):425–434. doi:10.4161/hv.4.6.6912.
  • Wei F, Guo M, Huang S, Li M, Cui X, Su Y, Wu X, Ma X, Zheng Y, Huang Y, et al. Sex differences in the incidence and clearance of anogenital human papillomavirus infection in Liuzhou, China: an observational cohort study. Clin Infect Dis. 2020;70(1):82–89. doi:10.1093/cid/ciz168.
  • Giuliano AR, Nyitray AG, Kreimer AR, Pierce Campbell CM, Goodman MT, Sudenga SL, Monsonego J, Franceschi S. EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection. Int J Cancer. 2015;136(12):2752–2760. doi:10.1002/ijc.29082.
  • WHO. Global health sector strategy on sexually transmitted infections 2016–2021-towards ending STIs. Geneva, Switzerland: World Health Organization; 2016.
  • WHO. Draft global health sector strategies-sexually transmitted infections, 2016–2021. Geneva, Switzerland: World Health Organization; 2016.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.